Gracell Biotechnologies

As a member of the AstraZeneca Group, Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing novel autologous and allogeneic cell therapies for cancer and autoimmune diseases. Since its inception, Gracell has established a solid inhouse R&D system. Leveraging its proprietary FasTCAR and TruUCAR technology platforms and SMART CART™ technology modules, Gracell is researching new ways to address current challenges with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal T cell quality and barriers that limit their activity in solid tumors and autoimmune diseases.